b.value AG — Deutsche Bio­tech­no­lo­gie Beteiligungsaktiengesellschaft

As one of the first Ger­man bio­tech­no­logy invest­ment com­pan­ies, b.value AG aims to fully devel­op the eco­nom­ic poten­tial of bio-based tech­no­lo­gies from the fields of indus­tri­al bio­tech­no­logy, life sci­ence and chem­istry in the com­mon interest of founders and investors. Oper­a­tion­ally act­ive since 2017, b.value AG invests in seed stage com­pan­ies in Ger­man-speak­ing coun­tries as a minor­ity and major­ity stake­hold­er in almost all cases togeth­er with oth­er co-investors.

To cope with the diversity and com­plex­ity of the sci­ence-driv­en and high-tech sec­tor, the oper­a­tion­al b.value team is char­ac­ter­ized by an extraordin­ary tech­no­lo­gic­al spe­cial­iz­a­tion and com­bines in its man­age­ment more than 40 years of lead­er­ship exper­i­ence in the devel­op­ment of tech­no­logy com­pan­ies as well as the com­mer­cial­iz­a­tion of bio­tech­no­lo­gic­al devel­op­ments. In addi­tion to the high level of spe­cial­iz­a­tion and a deep under­stand­ing of the industry, the port­fo­lio com­pan­ies bene­fit from b.value’s unique ​“com­pany-build­ing” approach as well as a wide net­work of sci­ent­ists, exec­ut­ives, policy makers and indus­tri­al and aca­dem­ic thought leaders.